Better Health for All

IGM Biosciences is a biotechnology company focused on developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. This core business model is entirely dedicated to health improvement. However, Phase 1b studies for imvotamab and IGM-2644 in rheumatoid arthritis and systemic lupus erythematosus showed insufficient B cell depletion, leading to the termination of these specific programs in January 2025.

The company continues to advance other candidates, including aplitabart for colorectal cancer, and other trials for imvotamab and IGM-2644 in different indications. The company's R&D expenses were $43.8 million in Q1 2024 and $42.0 million in Q2 2024. Its projected 2024 GAAP operating expenses are $210 million to $220 million, which means R&D expenses represent approximately 19.1% to 20.9% of operating expenses. The company has an Individual Patient Expanded Access (IPEA) policy for investigational drugs outside of clinical trials, which includes patient eligibility criteria, physician qualifications, and an IPEA Committee review process emphasizing ethical considerations and risk/benefit assessments.

Fair Pay & Worker Respect

Employee engagement is rated at 3.1 out of 5 stars, which is approximately 62% based on 34 reviews.

The company processed a Worker Adjustment and Retraining Notification Act (WARN) notice on January 14, following an announced 73% workforce reduction affecting 100 employees, effective March 10. This reduction came after a 22% staff cut in December 2023. The company's Code of Ethics and Conduct states compliance with local wage and hour laws, warrants freedom of association and collective negotiation, and prohibits discrimination in remuneration and promotion. It also outlines 10 Life Saving Rules for safety and applies to temporary workers, and prohibits retaliation against whistleblowers.

Honest & Fair Business

IGM Biosciences maintains a confidential and anonymous financial concern hotline, established in compliance with SEC regulations for Audit Committees.

This hotline allows for the submission of complaints related to accounting, internal controls, or auditing matters. However, the provided information does not detail independent investigation processes, training, or the effectiveness of this policy.

Kind to Animals

IGM Biosciences conducts animal testing, with procedures approved by the University of Houston Institutional Animal Care and Use Committee (IACUC), Bioqual Inc.’s IACUC, and the University of Texas Medical Branch IACUC.

These studies are conducted in accordance with recommendations from the Office of Laboratory Animal Welfare, National Institutes of Health. This indicates a policy where testing is subject to regulatory oversight, implying that discretionary testing is prohibited, but legally mandated studies proceed. Annually, the company uses between 10,000 and 15,000 animals, including mice (CD-1, BALB/c) and rats, for biodistribution, efficacy, and safety studies.

No War, No Weapons

IGM Biosciences, Inc. is a biotechnology company focused on developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. As of December 31, 2024, the company reported $183.8 million in cash and investments.

It has an exclusive worldwide collaboration agreement with Sanofi to develop, manufacture, and commercialize IgM antibody agonists for immunology and inflammation targets. The provided articles do not contain any specific, concrete data points or information regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any other activities relevant to the "No War, No Weapons" ethical value.

Respect for Cultures & Communities

No specific, concrete evidence was found in the provided articles that directly addresses any of the KPIs for IGM Biosciences, Inc. (IGMS.US) related to Respect for Cultures & Communities. Articles pertain to different entities, IGM Financial

and IGM Resins , respectively, and therefore their content is not applicable to IGMS.US. Article , which is about IGM Biosciences, Inc., does not contain quantifiable data points for the specified KPIs.